Scanditronix was omitted in our last issue from a list of vendors(SCAN 7/31/91) that have developed negative-ion cyclotrons--so-calledbaby cyclotrons--for the production of positron emission tomographyradiopharmaceuticals. Negative-ion machines don't
Scanditronix was omitted in our last issue from a list of vendors(SCAN 7/31/91) that have developed negative-ion cyclotrons--so-calledbaby cyclotrons--for the production of positron emission tomographyradiopharmaceuticals.
Negative-ion machines don't produce the radiation that traditionalPET cyclotrons generate, so shielding requirements are reduced.The lower shielding requirement trims manufacturing and sitingcosts, which in turn reduces the overall cost of operating a PETsystem (see story, page one).
GE Medical Systems, which purchased the Scanditronix PET camerabusiness early last year (SCAN 12/13/89), is exclusive distributorof the PETtrace 200 cyclotron, said Dow R. Wilson, GE PET marketingmanager.
With GE marketing the Scanditronix negative-ion system, allthree major PET vendors--Siemens, Positron and GE--now offer thelower cost technology.
The PETtrace 200 is a dual-particle cyclotron. The advantageof this technology is that two targets can be irradiated at once,producing two different isotopes simultaneously, Wilson said.
"This is beneficial if you have a big program or multiplescanners that you are supporting," he said.
The Scanditronix cyclotron can produce oxygen-15, nitrogen-13,carbon-11 and fluorine-18 PET tracers.
GE's relationship with Scanditronix works well for both sides,Wilson said. The world's largest medical imaging equipment vendorhas no desire to build cyclotrons.
"We want to stick to our knitting," he said. "Weare an image processing and sales and service company. We don'twant to be an accelerator manufacturer. Scanditronix is as goodat that as anyone--maybe better. We want them to stick to theirknitting, so they can engineer and manufacture a state-of-the-artcyclotron, and we can market it for them."
MRI-Based Deep Learning Algorithm Shows Comparable Detection of csPCa to Radiologists
May 8th 2024In a study involving over 1,000 visible prostate lesions on biparametric MRI, a deep learning algorithm detected 96 percent of clinically significant prostate cancer (csPCa) in comparison to a 98 percent detection rate for an expert genitourinary radiologist.
FDA Clears AI-Powered Qualitative Perfusion Mapping for Cone-Beam CT
May 6th 2024Reportedly validated in more than 10 clinical trials, the AngioFlow perfusion imaging software enables timely identification of brain regions with cerebral blood flow reduction and those with significant hypoperfusion.